Compounders Research Compare

Damora Therapeutics, Inc.(DMRA)

Biotechnology · Waltham, MA

$19.55-0.67 (-3.31%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Damora Therapeutics, Inc.

Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.

Waltham, MA

7 employees

www.damoratx.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Jennifer A. Jarrett

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T21:11:34.818Z.

Stored calculation inputs

Calculation as of: 2026-10-06T21:11:34.818Z.

Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,203,364,943
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 540,515,000
TTM free cash flow · period ending 2026-06-30: N/A

FMP input reference: 4140271b5ba2e17517ffa776ba39ee0784cb590c71b20d0313403f3757235181

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DMRA EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

DMRA Competitors' EV/FCF Ratio

Damora Therapeutics, Inc.

Current

Market Cap

$1.20B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kardigan, Inc.

Market Cap

$1.21B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Tyra Biosciences, Inc.

Market Cap

$1.21B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Innovage Holding Corp.

Market Cap

$1.22B

EV/FCF Ratio

23.98x

TTM Avg

28.78x

3Y Avg

30.44x

5Y Avg

41.95x

MannKind Corporation

Market Cap

$1.18B

EV/FCF Ratio

N/A

TTM Avg

74.41x

3Y Avg

125.98x

5Y Avg

125.98x

Cronos Group Inc.

Market Cap

$1.23B

EV/FCF Ratio

15.32x

TTM Avg

580.30x

3Y Avg

501.54x

5Y Avg

501.54x

Omada Health

Market Cap

$1.23B

EV/FCF Ratio

50.31x

TTM Avg

50.12x

3Y Avg

50.12x

5Y Avg

50.12x

ORIC Pharmaceuticals, Inc.

Market Cap

$1.24B

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Nektar Therapeutics

Market Cap

$1.14B

EV/FCF Ratio

N/A

TTM Avg

9.20x

3Y Avg

9.20x

5Y Avg

9.20x

Amphastar Pharmaceuticals, Inc.

Market Cap

$1.14B

EV/FCF Ratio

10.51x

TTM Avg

12.48x

3Y Avg

15.43x

5Y Avg

19.92x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
Damora Therapeutics, Inc. (DMRA)	$1.20B	N/A	N/A	N/A	N/A
Kardigan, Inc. (KARD)vs ›	$1.21B	N/A	N/A	N/A	N/A
Tyra Biosciences, Inc. (TYRA)vs ›	$1.21B	N/A	N/A	N/A	N/A
Innovage Holding Corp. (INNV)vs ›	$1.22B	23.98x	28.78x	30.44x	41.95x
MannKind Corporation (MNKD)vs ›	$1.18B	N/A	74.41x	125.98x	125.98x
Cronos Group Inc. (CRON)vs ›	$1.23B	15.32x	580.30x	501.54x	501.54x
Omada Health (OMDA)vs ›	$1.23B	50.31x	50.12x	50.12x	50.12x
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.24B	N/A	N/A	N/A	N/A
Nektar Therapeutics (NKTR)vs ›	$1.14B	N/A	9.20x	9.20x	9.20x
Amphastar Pharmaceuticals, Inc. (AMPH)vs ›	$1.14B	10.51x	12.48x	15.43x	19.92x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics